Amgen Inc. has recently been in the spotlight following an interim analysis of its weight loss drug, MariTide. Although specific details were not disclosed, the company's public discussion suggests promising early results, hinting at blockbuster potential. Following this update, Cathie Wood's Ark Invest purchased $3.54 million worth of Amgen shares, increasing its stake in the biopharma company. This acquisition raised Amgen's weighting in the ARKG exchange-traded fund to 1.06%, with a total of 51,712 shares held. Analysts are assessing Amgen's potential to become a significant player in the weight loss drug market, potentially joining leaders like Novo Nordisk and Eli Lilly.
$AMGN | Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update Following Friday's purchase, Amgen's weighting in ARKG stood at 1.06%, attributed to the 51,712 shares held by the exchange-traded fund. The… https://t.co/sjxm770Ktw
1) $LLY's Rao "They can’t possibly be this good? he remembered thinking before presented the AI results" about "weird-looking structures that could not be matched to much in the company’s existing molecular database" $NVDA's Powell ... h/t @AndrewCurran_ https://t.co/60HyjvPoTa https://t.co/tHbxJxLiyV
5May: How do analysts assess @Amgen's ability to become the third powerhouse #WeightLoss drug developer after @novonordisk and @EliLillyandCo? Read about $AMGN's MariTide, plus updates on $ADXN, $ANVX, $CTMX, and $EBS in my latest StockWatch for @GENbio: https://t.co/HFAzPciHer
$AMGN Report was meh but teased data on their weight loss drug.... Big gap now, more data soon... another block buster possible here like $LLY https://t.co/jrx0OSvBVk
$AMGN — $LLY $NVO $VKTX For a company as litigious as $AMGN to talk up MariTide interim analysis without revealing any real details as publicly as it did… probably means that early results are even better than they let on. https://t.co/HkeEQu4K7K